×
Click here if you have patients on the Pushtronex® system (single-dose on-body infusor with prefilled cartridge) and need additional guidance on how to transition them with a new device prescription.
Click here if your patients are having issues using their co-pay card or their co-pay is higher than normal at the pharmacy.
Coverage Information | Repatha® (evolocumab)
INDICATIONS

Repatha® is indicated:

  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization... READ MORE

    • For US healthcare professionals

    REPATHA® HAS BROAD COVERAGE, AFFORDABILITY, AND ACCESS

    9
    out of
    10

    patients have formulary coverage for Repatha® (evolocumab)1

    79%

    Repatha® Claim Approval Rate2

    Repatha® May Cost Your Patients Less Than You Think

    COMMERCIAL

    $5

    Commercially insured patients may pay

    $5 a month

    with the Repatha® Co-Pay Card.

    MEDICAID

    99%

    of prescriptions cost patients

    $10 or less3

    MEDICARE

    ~71%

    of prescriptions cost patients

    $49 or less3,†

    Repatha® Access and Affordability Have Significantly Improved Over Time4

    Repatha® NRx Approval Rates

    Repatha® (evolocumab) NRx Access Rates Graph

    No Additional Documentation Required for the Majority of Lives With PCSK9i mAbs Coverage‡

    85%

    of commercial and health exchange lives in covered status for a PCSK9i require attestation only (no additional submission of documentation)1,††

    For Repatha® electronic prior authorizations submitted through CoverMyMeds§

    On average,

    ~40%

    received an instant determination within

    5 minutes5,**

    On average,

    ~80%

    received a determination within

    24 hours5,**

    Repatha® Patient Brochure DownloadRepatha® Patient Brochure Download

    Help Patients Start and Stay on Repatha® A reference for you and your office staff to help patients start and stay on Repatha®, including where to find tools, resources, prior authorization information, example ICD-10 codes as well as Co-Pay card information.*

    NRx, new prescription; PCSK9, proprotein convertase subtilisin/kexin type 9; PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor.

    *Subject to eligible criteria and program maximums. Visit www.repatha.com/copay for full terms and conditions.

    †The patient out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in. Medicare Part D drug coverage is divided into four phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.

    ‡Eligibility and program maximums apply. Terms and Conditions apply.

    §Amgen®, the marketer of Repatha®, has entered into a fee-for-service arrangement with CoverMyMeds to provide a differentiated ePA experience after you have chosen to prescribe Repatha®. CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.

    **Data from January 1, 2022 through December 31, 2022, measuring time between when a complete ePA is submitted to the health plan and determination is received by the HCP. These statistics are subject to change and are based upon a multitude of factors that can influence turnaround time.

    ††All claims were approved with an attestation only through CoverMyMeds.

    References: 1. Data on file. Amgen; [1]; 2021. 2. Data on file. Amgen; [2]; 2022. 3. Data on file, Amgen; [3]; 2021. 4. Data on file, Amgen; [4]; 2022. 5. Data on file, Amgen; [Repatha ePA Turnaround Times 01 Jan 2022 through 31 Dec 2022 from CoverMyMeds. March 2023].

    Important Safety Information

    Contraindications: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.
    • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.

    Please see full Prescribing Information.

    Important Safety Information

    Contraindications: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Back To Top